Group 1 - The core viewpoint of the article highlights that the photovoltaic silver paste industry generally adopts a pricing model based on "silver price + processing fee," with the risk of silver price fluctuations primarily borne by downstream customers [1] - The company's strategic focus in the photovoltaic sector is on providing cost-reduction technology solutions that utilize non-silver or low-silver products, such as electroplated copper [1] - The electroplated copper process can achieve "copper instead of silver," fundamentally reducing the consumption of precious metals and helping customers establish a long-term, stable cost advantage [1]

（编辑 丛可心） 证券日报网讯 2月3日，四川双马在互动平台回答投资者提问时表示，公司近年完成了对生物医药企业 深圳健元的收购，进一步拓展了公司未来发展板块，经营发展活力进一步增强。未来公司将在夯实投资 板块的同时持续推动生物医药业务的深入发展，不断提升运营效能，努力为股东创造更多价值与回报。 ...

（编辑 王雪儿） 证券日报网讯 2月3日，瑞达期货在互动平台回答投资者提问时表示，瑞达期货旗舰版APP及公司官 网，均已上线瑞达智能客服，其中运用了大模型技术支撑及针对性训练；智能投研系统目前还在研发 中。 ...

（编辑 王雪儿） 证券日报网2月3日讯 ，气派科技在接受调研者提问时表示，2026年公司全力以赴提高公司规模，一方 面随着行业景气度回暖，以及目前原材料、设备等上下游的涨价趋势，公司将结合实际情况逐步推动不 同产品的价格调整；另一方面公司将根据本次行业周期的恢复调整公司产品结构、产能分配。 ...

Core Viewpoint - The company focuses on the research, production, and sales of high-purity polysilicon products, primarily catering to the large-scale installation demand of ground photovoltaic systems, while also recognizing the potential of space photovoltaic applications as a significant direction for the solar industry [1] Group 1: Business Focus - The company's main business is centered on high-purity polysilicon products [1] - The core matching of the company’s offerings is primarily aligned with the demand for large-scale ground photovoltaic installations [1] Group 2: Space Photovoltaic Potential - Space photovoltaic applications have unique material requirements due to their specific usage scenarios, differing from ground photovoltaic systems [1] - The long-term development value and industrial potential of space photovoltaic technology are seen as promising, with expectations for expanded opportunities in the industry [1] Group 3: Future Exploration - The company will continue to monitor technological breakthroughs, material demand iterations, and the commercialization pace in the space photovoltaic field [1] - If the technological pathways in this sector become clearer, the company will cautiously evaluate and actively explore layout opportunities that align with its strategic development rhythm [1]

Group 1 - The company, Zongheng Communication, is a service provider for apps like Tencent's Yuanbao and ByteDance's Doubao, indicating its role in the digital service ecosystem [1] - The company anticipates an increase in traffic and user engagement across major platforms during the Spring Festival, which is expected to positively impact its business [1]

证券日报网讯 2月3日，太平洋在互动平台回答投资者提问时表示，公司无应披露未披露信息，有关公 司信息请以公告为准。本次变更股东申请尚需取得中国证监会核准，最终结果存在不确定性。公司将根 据进展情况及时履行信息披露义务。 （编辑 任世碧） ...

Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, has received acceptance for the marketing authorization application of Roflumilast cream (ZORYVE®) 0.05%, aimed at treating mild to moderate atopic dermatitis in children aged 2 to 5, marking a significant milestone in the product's development and enhancing the company's competitive edge in autoimmune skin treatments [1][2]. Group 1: Product Development and Market Position - The active ingredient of ZORYVE® is Roflumilast, a highly selective non-steroidal phosphodiesterase-4 (PDE4) inhibitor that reduces inflammation by inhibiting the production of pro-inflammatory mediators [1]. - The cream is part of a collaboration with Arcutis Biotherapeutics, Inc., granting Huadong Medicine exclusive rights for development, registration, production, and commercialization in Greater China and Southeast Asia [1]. - The application targets a significant unmet need in the market, particularly for children aged 2 to 5, where treatment options are currently limited to traditional topical corticosteroids and calcineurin inhibitors [2]. Group 2: Market Demand and Clinical Need - There are approximately 67 million atopic dermatitis patients in China, indicating a substantial unmet clinical demand [2]. - The prevalence of atopic dermatitis in children aged 1 to 7 is reported at 12.94%, highlighting the urgent need for safe and effective treatment options for this age group [2]. - The acceptance of the 0.05% cream application is expected to provide new treatment options for pediatric patients, establishing a differentiated market barrier and first-mover advantage for Huadong Medicine in a competitive landscape [2]. Group 3: Broader Product Portfolio - Huadong Medicine has developed a differentiated product pipeline that includes various concentrations of Roflumilast cream, with higher concentrations (0.15% and 0.3%) also having received regulatory acceptance for treating older patients with atopic dermatitis and psoriasis [3]. - Additionally, a foam formulation of Roflumilast (ZORYVE®) 0.3% for seborrheic dermatitis in patients aged 9 and above is currently undergoing Phase III clinical trials [3].

（编辑 王雪儿） 证券日报网讯 2月3日，荣盛石化在互动平台回答投资者提问时表示，截至2025年三季度末，公司的股 东人数为73726户。截至2025年四季度末公司的股东人数，公司将于2025年年度报告中披露。 ...

Group 1 - The core announcement is regarding the judicial freeze and subsequent release of shares held by a major shareholder of the company, Shenzhen Bo Heng Investment Co., Ltd. [1] - On June 10, 2025, the company disclosed that a total of 15,114,647 shares held by Bo Heng Investment were frozen by the Hangzhou Intermediate People's Court in Zhejiang Province [1] - Recently, the company confirmed through the China Securities Depository and Clearing Corporation Limited Shenzhen Branch that the aforementioned shares have been released from judicial freeze [1]